OncoMatch/Clinical Trials/NCT06712121
Venetoclax and Decitabine in R/R T-ALL
Is NCT06712121 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies decitabine plus venetoclax for t lymphoblastic leukemia/lymphoma.
Treatment: decitabine plus venetoclax — The goal of this phase 2 clinical trial is to test the efficacy of decitabine and venetoclax combination chemotherapy in relapsed or refractory adult T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. This study use a modified regimen of decitabine and venetoclax.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: induction chemotherapy
relapse or failure to achieve complete remission despite induction chemotherapy
Cannot have received: venetoclax + decitabine (venetoclax, decitabine)
Exception: participants who received venetoclax + decitabine treatment for a different type of cancer (e.g., acute myeloid leukemia) and have elapsed more than 1 year since the last treatment are allowed
Individuals who previously received venetoclax + decitabine treatment for T-lymphoblastic leukemia/lymphoma
Lab requirements
Blood counts
peripheral blood leukocytes <50,000/uL (reducing white blood cell count through hydroxyurea or leukapheresis prior to trial enrollment is allowed)
Kidney function
calculated GFR ≥ 30 mL/min according to Cockcroft-Gault formulas, or creatinine ≤ 1.4
Liver function
total bilirubin ≤ 3.0 mg/dL, AST and ALT < x5 upper limit of normal (ULN); if bilirubin elevation is due to Gilbert's syndrome or liver enzyme elevation is due to infiltration of leukemia/lymphoma, enrollment may be allowed even if the above conditions are exceeded
peripheral blood leukocytes <50,000/uL (reducing white blood cell count through hydroxyurea or leukapheresis prior to trial enrollment is allowed); calculated GFR ≥ 30 mL/min according to the Cockcroft-Gault formulas, or creatinine ≤ 1.4, total bilirubin ≤ 3.0 mg/dL, and AST and ALT < x5 upper limit of normal (ULN) (however, if bilirubin elevation is due to Gilbert's syndrome or liver enzyme elevation is due to infiltration of leukemia/lymphoma, enrollment may be allowed even if the above conditions are exceeded)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06712121 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior venetoclax + decitabine disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger and at least 19 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify